Following my earlier post on this issue, it is now reported that the Indian Patent Office (IPO) has refused patent to the anti-cancer drug, Abraxane. I am yet to obtain a copy of this IPO order.
A recap
Briefly, the opposition against the patent application for Abraxane was filed by Natco Pharma with the IPO and was decided against the patent applicant, Abraxis Biosciences (“Abraxis”). Abraxis appealed against the IPO’s order with the Intellectual Property Appellate Board (IPAB) owing to certain procedural lapses. IPAB agreed with Abraxis and asked the IPO to consider the opposition afresh.
What’s new?
The recent order of the IPO is said to have stated the following:
“The amended claims (here Abraxis Boisciences) lack inventive step and do not constitute an invention under the Patents Act, 1970.”
I will update this post and discuss the IPO’s order in detail once I peruse the order.
Raja Selvam
Founder & Managing Attorney, Selvam & Selvam | Practice areas include Trademarks, Patents, Domain names & Business law. Visiting faculty, Department of Journalism, Madras University where I teach copyrights & trademarks law. Passionate about entrepreneurship, start-ups, stocks, farming, technology and law.
Controller of Patents has the power to condone delay in filing responses to Examination Report – Madras High Court.
Justice Anita Sumanth, presiding over the case, emphasized that the delay was only four days and that the Controller had not considered the…
Physical presence of your goods or services is not required to protect your trademark in India
The case of trademark infringement and passing off was filed by EASYGROUP IP LICENSING LIMITED (the plaintiff) in respect of the alleged infringement…
Effectiveness of RTI for your trademark applications
There are several resources online that will tell you how to register your trademark in India, with a neatly drawn flow chart for clarity and some…